Furiex Pharmaceuticals, Inc. (FURX) Reports a Q2 loss
Tweet Send to a FriendGet Alerts FURX Hot Sheet
Trade FURX Now!
Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) reported Q2 EPS of ($2.09), $1.62 worse than the analyst estimate of ($0.47) (May not be comparable).
Revenue for the quarter came in at $13.1 million versus the consensus estimate of $10.12 million.
For earnings history and earnings-related data on Furiex Pharmaceuticals, Inc. (FURX) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Revenue for the quarter came in at $13.1 million versus the consensus estimate of $10.12 million.
For earnings history and earnings-related data on Furiex Pharmaceuticals, Inc. (FURX) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Applied Materials, Inc. (AMAT) Tops Q2 EPS by 3c, Offers Guidance
- Notable Winners and Losers from Q1 Earnings Season: (YRCW) (TSLA) (AVEO) (CRMB)
- Autodesk, Inc. (ADSK) Misses Q1 EPS by 3c, Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
